ArticleGlycoconjugate journal2015
Expression of ST3Gal, ST6Gal, ST6GalNAc and ST8Sia in human hepatic carcinoma cell lines, HepG-2 and SMMC-7721 and normal hepatic cell line, L-02.
Article in Glycoconjugate journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 7 citations in OpenAlex.
- Identification and Experimental Validation of the Prognostic Significance and Immunological Correlation of Glycosylation-Related Signature and ST6GALNAC4 in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023Article
- Sialyltransferase Inhibitors for the Treatment of Cancer Metastasis: Current Challenges and Future Perspectives.Molecules (Basel, Switzerland) · 2021Review
- Comprehensive quali-quantitative profiling of neutral and sialylatedRSC advances · 2019Article
- Overexpression of ST3Gal-I promotes migration and invasion of HCCLM3 in vitro and poor prognosis in human hepatocellular carcinoma.OncoTargets and therapy · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We measured ST3Gal, ST6Gal, ST6GalNAc and ST8Sia expression in human hepatic carcinoma cell lines, HepG-2 and SMMC-7721 and normal hepatic cell line, L-02 to reveal the relationship between hepatic carcinoma cell lines sialyltransferases expression and cell membrane sialic acid sugar chains. Membrane sialic acid sugar chains in L-02, HepG-2 and SMMC-7721 cell lines were measured with lectin microarrays to find expression profiles. Expression of 20 sialyltransferases was measured with DNA microarray. qRT-PCR and Western blot were used to verify DNA microarrays data. Siaα 2-3Galβ1-3[Siaα2-6GalNAc]α-R and Siaα 2-6Gal/GalNAc sugar chains in hepatic carcinoma cell lines, HepG-2 and SMMC-7721 were upregulated, and 7differentially expressed sialyltransferases were captured. ST3Gal-IV and ST6Gal I were overexpressed and ST3Gal-I, ST3Gal-V, ST3Gal-VI, ST6GalNAcII and ST6GalNAcVI were downregulated in HepG-2 and SMMC-7721 cell Lines, compared with control cell line. ST6GalNAc-IV and ST8sia expressions were not detected. Other sialyltransferases were not different among cell lines. Results from qRT-PCR and Western blot were consistent with DNA microarray. Overexpression of ST3Gal-IV and ST6Gal I in HepG-2 and SMMC-7721 cell lines may correlate with upregulation of Siaα 2-3Galβ1-3[Siaα2-6GalNAc]α-R and Siaα 2-6Gal/GalNAc sugar chains on cell membranes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.